The need to accelerate access to new drugs for multidrug-resistant tuberculosis

Approximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10% are successfully treated. Poor access to treatment is probably driving the current epidemic, via ongoing transmi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Helen S, Furin, Jennifer J, Mitnick, Carole D, Daniels, Colleen, Cox, Vivian, Goemaere, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Health Organization 2015
Materias:
Policy & Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490806/
https://www.ncbi.nlm.nih.gov/pubmed/26170507
http://dx.doi.org/10.2471/BLT.14.138925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490806/
https://www.ncbi.nlm.nih.gov/pubmed/26170507
http://dx.doi.org/10.2471/BLT.14.138925

Ejemplares similares